Article

Validation of defocus tolerance of novel aberration-neutral hydrophobic acrylic monofocal IOL

Author(s):

Julianne Mobilian
Conferences|ASCRS

Eva Liang, MD, discusses the take-home message from her presentation at ASCRS 2019

Eva Liang, MD, discusses the take-home message from the presentation she delivered at the 2019 meeting of the American Society of Cataract and Refractive Surgery: "Validation of Defocus Tolerance of Novel Aberration-neutral Hydrophobic Acrylic Monofocal IOL."

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
Related Content
Q&A: Eva Kim, MD, on the value of EVO ICL for patients considering surgery
May 18th 2025

Q&A: Eva Kim, MD, on the value of EVO ICL for patients considering surgery

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Ravi Patel, MD, shares ASCRS 2025 insights on enVista ASPIRE IOL user experience
May 11th 2025

Ravi Patel, MD, shares ASCRS 2025 insights on enVista ASPIRE IOL user experience

Evaluating safety, efficacy of TP03 for Demodex blepharitis treatment
July 26th 2021

Evaluating safety, efficacy of TP03 for Demodex blepharitis treatment

Subretinal drusenoid deposits: Marker for unrecognized cardiac disease
May 6th 2025

Subretinal drusenoid deposits: Marker for unrecognized cardiac disease

(Image credit: AdobeStock/Roman)
April 30th 2025

ASCRS 2025: Visual and patient-reported outcomes following bilateral Odyssey implantation

© 2025 MJH Life Sciences

All rights reserved.